| Literature DB >> 23209575 |
Dafna Ben Bashat1, Moran Artzi, Haim Ben Ami, Orna Aizenstein, Deborah T Blumenthal, Felix Bokstein, Benjamin W Corn, Zvi Ram, Avraham A Kanner, Biatris Lifschitz-Mercer, Irit Solar, Tsafrir Kolatt, Mika Palmon, Yifat Edrei, Rinat Abramovitch.
Abstract
Blood oxygenation level dependence (BOLD) imaging under either hypercapnia or hyperoxia has been used to study neuronal activation and for assessment of various brain pathologies. We evaluated the benefit of a combined protocol of BOLD imaging during both hyperoxic and hypercapnic challenges (termed hemodynamic response imaging (HRI)). Nineteen healthy controls and seven patients with primary brain tumors were included: six with glioblastoma (two newly diagnosed and four with recurrent tumors) and one with atypical-meningioma. Maps of percent signal intensity changes (ΔS) during hyperoxia (carbogen; 95%O2+5%CO2) and hypercapnia (95%air+5%CO2) challenges and vascular reactivity mismatch maps (VRM; voxels that responded to carbogen with reduced/absent response to CO2) were calculated. VRM values were measured in white matter (WM) and gray matter (GM) areas of healthy subjects and used as threshold values in patients. Significantly higher response to carbogen was detected in healthy subjects, compared to hypercapnia, with a GM/WM ratio of 3.8 during both challenges. In patients with newly diagnosed/treatment-naive tumors (n = 3), increased response to carbogen was detected with substantially increased VRM response (compared to threshold values) within and around the tumors. In patients with recurrent tumors, reduced/absent response during both challenges was demonstrated. An additional finding in 2 of 4 patients with recurrent glioblastoma was a negative response during carbogen, distant from tumor location, which may indicate steal effect. In conclusion, the HRI method enables the assessment of blood vessel functionality and reactivity. Reference values from healthy subjects are presented and preliminary results demonstrate the potential of this method to complement perfusion imaging for the detection and follow up of angiogenesis in patients with brain tumors.Entities:
Mesh:
Substances:
Year: 2012 PMID: 23209575 PMCID: PMC3507885 DOI: 10.1371/journal.pone.0049416
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Patients' clinical information.
| Patient No | Age (y) | Gender | Diagnosis | Treatment |
| 1 | 64 | F | Atypical Meningioma | Untreated |
| 2 | 26 | M | Glioblastoma | Untreated |
| 3 | 34 | M | Glioblastoma | Untreated |
| 4 | 74 | F | Recurrent Glioblastoma | RT+Chemo |
| 5 | 45 | M | Recurrent Glioblastoma | RT+Chemo |
| 6 | 58 | M | Recurrent Glioblastoma | RT+Chemo |
| 7 | 41 | M | Recurrent Glioblastoma | RT+Chemo |
y = years; M/F = male/female; RT = radiation therapy; Chemo = chemotherapy;
Figure 1Hemodynamic Response Imaging in the healthy brain.
Representative HRI results obtained from a 29 year old healthy subject. (A) ΔS-O2 map; (B) ΔS-CO2 map; (C) the corresponding T1-weighted (anatomical) image; (D) the gray and white matter masks (GM and WM, respectively); the mean time courses of the signal intensity change (%) during hyperoxic challenge (E) and hypecapnic (F) challenges, calculated from the GM VOI of this subject.
Means and standard deviations of HRI values calculated from all healthy subjects.
| GM | WM | GM/WM | |
| ΔS-O2 | 2.54±0.63 | 0.71±0.30 | 3.84±1.01 |
| ΔS-CO2 | 1.33±0.33 | 0.40±0.24 | 3.69±0.98 |
| VRM | 0.50±0.15 | 0.22±0.10 |
ΔS = percent signal intensity changes; GM = gray matter; WM = white matter; VRM = vascular reactivity mismatch.
HRI and rCBV values calculated at the lesion and contra lateral side VOIs.
| Patient No | rCBV | ΔS-O2 (%) | ΔS-CO2(%) | Vascular reactivity index | |||||
| lesion | CLS | lesion | CLS | lesion | CLS | lesion | CLS | ||
| 1 | Atypical Meningioma | 8.2 | 1.9 | 3.32 | 2.82 | 1.09 | 0.93 | 19% | 9% |
| 2 | Glioblastoma | 2.5 | 1.2 | 1.94 | 1.93 | 0.72 | 1.08 | 27% | 7% |
| 3 | Glioblastoma | 4.1 | NA | 1.10 | NA | 0.33 | NA | 13% | NA |
| 4 | Recurrent Glioblastoma | 2.6 | 1.7 | 1.00 | 2.02 | 0.19 | 0.60 | 12% | 7% |
| 5 | Recurrent Glioblastoma | 3.7 | 1.9 | 1.05 | 1.93 | 0.38 | 0.87 | 15% | 10% |
| 6 | Recurrent Glioblastoma | NA | NA | 1.07 | 1.50 | 0.63 | 0.80 | 2% | 12% |
| 7 | Recurrent Glioblastoma | NA3 | NA3 | 0.55 | 1.48 | 0.09 | 0.15 | 13% | 43% |
ΔS = percent signal intensity changes; rCBV = relative cerebral blood volume; CLS = contralateral side.
Vascular reactivity index, number of voxels (in percentages) above the defined VRM threshold.
Lesion crosses brain midline, thus contralateral side VOI could not be defined.
DSC perfusion was not performed.
Figure 2Hemodynamic Response Imaging in patients.
HRI results obtained from a patient with atypical meningioma (Left; patient number 1) and from a patient with newly diagnosed glioblastoma (Right; patient number 3); For both patients a representative coronal slice through the tumor center of (A) ΔS-O2 maps, (B) ΔS-CO2 maps, (C) VRM maps (of the tumors area which are marked by white rectangle on figures A and B) and (D) rCBV maps. All the maps are superimposed on the anatomical images. Color scales for all maps are located on the right side. PSC- percent signal change; SD- standard deviation.
Figure 3Hemodynamic Response Imaging and pathological findings.
Results obtained from a newly diagnosed patient with GB (patient number 2). Representative sagital (left), axial (center) and coronal (right) orientations taken through the tumor center of (A) T1-weighted images; (B) ΔS-O2 maps; (C) ΔS-CO2 maps; (D) VRM maps (of the tumor area marked by white rectangle on figure 3B,C) and (E) rCBV maps. The maps are superimposed on the anatomical images; color scales for all maps are located on the right side. Immunohistochemical staining of samples from the same tumor with: (F) Ki67 antibody for proliferation; (G) CD31 antibody for endothelial cells indicating vascularity and (H) SMA antibody for smooth muscle cells indicating vascular maturation.
Figure 4Negative
ΔS-O2 response. Representative results obtained from a patient with recurrent GB (patient number 4), showing negative ΔS-O2 response during hyperoxic challenge observed distant from the tumor area. (A) ΔS-O2 map; (B) T1WI post contrast agent injection and (C) fluid attenuation inversion recovery (FLAIR) image. (D) The mean time courses of the signal intensity change (%) during hyperoxic challenge obtained from the area with negative response (VOI is marked by red rectangle on Figure 4A).